Holen Sie sich die Stockscreener-App
76.43
2.43%
1.82
Handel nachbörslich:
76.32
-0.11
-0.14%
Schlusskurs vom Vortag:
$74.61
Offen:
$73.86
24-Stunden-Volumen:
537.55K
Relative Volume:
0.89
Marktkapitalisierung:
$3.47B
Einnahmen:
$1.36B
Nettoeinkommen (Verlust:
$123.81M
KGV:
31.71
EPS:
2.41
Netto-Cashflow:
$20.35M
1W Leistung:
+4.60%
1M Leistung:
+12.86%
6M Leistung:
-2.13%
1J Leistung:
-7.63%
1-Tages-Spanne:
$73.86
$76.95
1-Wochen-Bereich:
$72.39
$76.95
52-Wochen-Spanne:
$55.30
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Vergleichen Sie HAE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
76.43 | 3.47B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
136.25 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.80 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.83 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.74 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.20 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Kalkine: Haemonetics (NYSE:HAE) Reflects Unique Sector Metrics in the russell 1000 - Kalkine Media
Haemonetics at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Blood Platelets Market Deep Research Report with Forecast - openPR.com
Haemonetics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com
Transcript : Haemonetics Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Zacks Research Decreases Earnings Estimates for Haemonetics - Defense World
Q3 EPS Estimates for Haemonetics Decreased by Zacks Research - Defense World
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 36%? - Yahoo Finance
Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Haemonetics (HAE) – Investment Analysts’ Recent Ratings Updates - Defense World
Decoding Haemonetics Corp (HAE): A Strategic SWOT Insight - GuruFocus
HAEMONETICS CORP SEC 10-K Report - TradingView
JMP maintains Haemonetics stock $100 target post-results By Investing.com - Investing.com Canada
What 4 Analyst Ratings Have To Say About Haemonetics - Benzinga
Haemonetics (HAE) Stock Rating and Price Target Reaffirmed by JMP Securities | HAE Stock News - GuruFocus
JMP maintains Haemonetics stock $100 target post-results - Investing.com
Haemonetics Co. (NYSE:HAE) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Haemonetics Corporation (NYSE:HAE) Q4 2025 Earnings Call Transcript - Insider Monkey
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up - Yahoo Finance
Haemonetics’ (HAE) “Strong-Buy” Rating Reiterated at Raymond James - Defense World
Haemonetics Corporation Just Beat EPS By 8.7%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Haemonetics Full Year 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings - Yahoo Finance
Raymond James Reiterates Strong Buy on Haemonetics (HAE) with Lo - GuruFocus
Raymond James Reiterates Strong Buy on Haemonetics (HAE) with Lowered Price Target | HAE Stock News - GuruFocus
Raymond James Adjusts Haemonetics (HAE) Price Target to $105, Ma - GuruFocus
Haemonetics Corp (HAE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Challenges - GuruFocus
Haemonetics Corp (HAE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo Finance
Haemonetics (HAE) Rating Maintained, Price Target Lowered to $84 | HAE Stock News - GuruFocus
Haemonetics: Fiscal Q4 Earnings Snapshot - MySA
Transcript : Haemonetics Corporation, Q4 2025 Earnings Call, May 08, 2025 - marketscreener.com
Earnings call transcript: Haemonetics Q4 2025 beats EPS forecast, stock rises - Investing.com
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Haemonetics' Fiscal Q4 Adjusted Earnings Rise, Revenue Falls; Fiscal 2026 Outlook Issued - marketscreener.com
Haemonetics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Haemonetics earnings beat by $0.02, revenue topped estimates - Investing.com
Haemonetics (NYSE:HAE) Surprises With Q1 Sales - Yahoo Finance
Haemonetics Corp Surpasses Q4 Expectations with EPS of $1.17 and Revenue of $331 Million - GuruFocus
Haemonetics (HAE) Surpasses Q4 Revenue Expectations | HAE Stock News - GuruFocus
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website - Quantisnow
Haemonetics Corporation announces an Equity Buyback for $500 million worth of its shares. - marketscreener.com
Earnings To Watch: Haemonetics Corp (HAE) Reports Q4 2025 Result - Yahoo Finance
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Haemonetics Sues Terumo Over Plasma Tech Patents - Law360
Haemonetics (NYSE:HAE) Upgraded to “Buy” at StockNews.com - Defense World
Haemonetics (HAE) Expected to Announce Quarterly Earnings on Thursday - Defense World
BofA Securities’s latest rating for HAE stock - knoxdaily.com
Envestnet Asset Management Inc. Buys 4,217 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Taking on analysts’ expectations and winning: Haemonetics Corp (HAE) - Sete News
How Do Investors Really Feel About Haemonetics?Haemonetics (NYSE:HAE) - Benzinga
Bank of Montreal Can Sells 12,518,398 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.52%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):